Quality Investigations Audit Readiness
Verify your investigation system delivers thorough, timely, and defensible results
Overview
What's Inside
Investigation quality is one of the most critical indicators of a pharmaceutical site's compliance maturity. FDA investigators routinely pull investigation records to assess whether deviations are thoroughly investigated, root causes are evidence-based, OOS/OOT results follow defined phase processes, and CAPAs are verified for effectiveness. Weak investigations signal weak quality systems.
This checklist covers seven investigation domains: governance and SOP adherence with defined roles and accountability; deviation capture, classification, and root cause analysis methodology; OOS and OOT result management with phase-based processes; environmental excursion and product contamination investigations; complaint handling and adverse event escalation; CAPA implementation and effectiveness verification; and quality trends, metrics, and continuous improvement.
Each section includes Yes/No/NA audit questions drawn from real FDA inspection focus areas, covering investigation timelines, RCA methodology (5 Whys, Fishbone), evidence requirements, QA oversight, and the link between investigation outcomes and annual product quality reviews.
Why It Matters
Investigations are where quality systems are tested under pressure. FDA investigators judge a site's overall compliance by the quality of its investigations — are root causes evidence-based or assumption-based? Are OOS results properly phased? Are CAPAs verified for effectiveness? Investigation failures are among the most common 483 observations and the fastest route to warning letters.
What's Covered
Sections in this checklist
- Investigation governance, SOP adherence, and role accountability
- Deviation capture, classification, and escalation procedures
- Root cause analysis methodology and evidence-based conclusions
- OOS phase I/II processes and OOT statistical trending
- Environmental excursion and product contamination investigations
- Complaint handling timelines and adverse event escalation
- CAPA implementation, effectiveness verification, and KPI tracking
- Quality trends, metrics, and continuous improvement programmes
Who It's For
Target roles
Regulatory Basis
21 CFR 211.192, 21 CFR 211.198, ICH Q10, FDA OOS Guidance (2006), FDA Compliance Program 7356.002
Download Quality Investigations Audit Readiness
Enter your details once to unlock all Audit Hub resources. All future downloads are instant.
Related Checklists
Complaint Management Audit Readiness
End-to-end audit readiness checklist for pharmaceutical complaint management systems, covering complaint investigation thoroughness, root cause analysis, retain sample testing, CAPA linkage, and trending analysis aligned with FDA 483 focus areas.
CAPA Management Audit Readiness
Audit readiness checklist for CAPA systems covering initiation timeliness, root cause analysis quality, effectiveness checks, recurrence prevention, and management review integration — built from real FDA 483 observation patterns.
Quality Risk Management Audit Readiness (ICH Q9)
Comprehensive 100-point QRM audit checklist spanning all six FDA systems plus documentation, training, complaint management, and continuous improvement — structured as Yes/No/NA self-assessment questions aligned with ICH Q9 and ICH Q10.
Leucine is the first AI-native platform built for pharmaceutical manufacturing. It unifies quality management, regulatory compliance, and production operations into one intelligent system that powers your entire drug manufacturing lifecycle from raw materials to patient delivery.
